





































































Introduction	Pulmonary	 embolism	 (PE)	 is	 the	 third	most	 frequent	 acute	 cardiovascular	disease	after	acute	coronary	syndromes	and	stroke,	with	a	prevalence	of	80	to	 100	 cases/100.000	 persons	 per	 year	 [1].	 PE	 is	 associated	 with	 a	 wide	prognostic	spectrum,	ranging	from	prompt	resolution	of	symptoms	after	few	hours	of	 treatment	 to	sudden	death.	PE	patients	are	commonly	admitted	 to	hospital	for	their	initial	treatment,	though	some	of	them,	who	are	at	low	risk	of	 adverse	 outcomes	 (~1%	 of	 in-hospital	mortality),	may	 be	 suitable	 for	 a	short-hospital	stay	or	even	complete	home-treatment	[2-8].	 In	recent	years,	research	has	focused	on	stratifying	the	risk	of	adverse	outcomes	after	PE,	in	order	 to	 tailor	 treatment	 and	 management	 strategies.	 Although	 some	prognostic	 clinical	 prediction	models	 (CPM)	 have	 been	 adequately	 derived	and	validated,	especially	the	Pulmonary	Embolism	Severity	Index	(PESI)	and	its	simplified	version	(sPESI)	[9-11],	there	is	no	evidence	that	its	use	changes	clinicians	 behavior,	 improves	 PE	 patient	 outcomes	 or	 reduces	 costs	 [12].	Therefore,	 we	 planned	 to	 perform	 an	 impact	 analysis	 study	 to	 evaluate	 if	length	of	hospital-stay	 for	PE	varies	 according	 to	PE	 risk	of	 adverse	events	defined	by	PESI	in	common	clinical	practice.		








In	addition,	 a	historical	 cohort	was	 included	as	 control	 group,	 consisting	of	patients	diagnosed	with	PE	at	one	center	(Ospedale	di	Circolo,	Varese)	from	2005	 to	2009,	 to	 evaluate	 a	possible	 time-dependent	 trend	of	hospital	 stay	duration	for	PE.		




Anticipating	missing	data	for	PESI,	an	analysis	on	the	best	and	worst	clinical	scenario	 was	 planned,	 inputing	 missing	 data	 on	 PESI	 items	 as	 absence	 or	presence	of	the	condition,	respectively.		




(P=.264).	According	to	individual	PESI	classes,	the	median	hospital	stay	was	9	days	for	class	I,	9	for	class	II,	10	for	class	III,	11	for	class	IV,	10	for	class	V	(P=.662).	When	missing	 data	 on	 PESI	were	 analyzed	 according	 to	 the	 best	and	worst	clinical	scenarios,	the	difference	of	median	hospital	stay	between	the	low	risk	and.	high	risk	group	did	not	change	(9	vs.	10	days,	P=.008,	and		9	vs.	10	days,	P=.019,	respectively).	Possible	 predictors	 of	 prolonged	 hospital	 stay	 were	 analyzed	 by	 logistic	regression.	 In	 the	 final	 multivariate	 model,	 no	 variables	 were	 significantly	associated	with	 the	 length	of	hospital	 stay,	with	 the	exceptions	of	 impaired	renal	failure	(GFR,	<	50	mL/min)	and	anemia	(haemoglobin	<	10	g/dL)	that	were	 only	 marginally	 associated	 with	 a	 prolonged	 hospitalization	 (P=.057	and	.064,	respectively).		






























Last,	the	centers	were	located	in	northern	Italy,	thus	potentially	limiting	the	generalizability	of	the	results.	However,	the	multicenter	design	of	the	study,	including	eight	centers	from	four	different	regions,	may	increase	the	external	validity	of	the	results.	In	 conclusion,	 in	 this	 study	 the	 median	 length	 of	 hospital	 stay	 for	 PE	 was	generally	long.	The	difference	of	one	day	between	the	low-risk	and	high-risk	groups	 of	 patients	 according	 to	 sPESI	 was	 statistically,	 but	 not	 clinically	significant.	 Whether	 adopting	 PESI/sPESI	 in	 clinical	 practice	 can	 assist	clinicians	to	take	better	decisions	about	the	optimal	duration	of	hospital	stay	needs	to	be	prospectively	evaluated.		



































anticoagulation	should	be	given	for	a	minimum	of	3	months,	as	 for	patients	with	 proximal	 DVT	 [15].	 However,	 these	 recommendations	 are	 weak	 and	mainly	 based	 on	 low	 level	 of	 evidence.	 Indeed,	 a	 shorter	 course	 of	anticoagulation	(i.e.	4	to	6	weeks)	was	used	in	several	studies	[6,8,12,16-18]	and	favourable	results	were	found	when	compared	to	longer	durations	[8,12,	18].	Given	the	paucity	and	the	heterogeneity	of	available	information,	we	decided	to	 perform	 a	 retrospective	 cohort	 study	 aimed	 at	 evaluating	 the	 long-term	risk	 of	 recurrent	 VTE	 in	 consecutive	 patients	 diagnosed	with	 symptomatic	IDDVT,	 who	 received	 anticoagulant	 therapy	 according	 to	 a	 center-based	protocol,	and	were	followed-up	for	at	least	2	years.	
	




or	 severe	 renal	 failure),	 treatment	and	 follow-up	strategies	were	 left	 to	 the	treating	physician,	who	decided	on	 a	 case	by	 case	basis,	 and	patients	were	not	excluded	from	the	study.		Baseline	 characteristics	 were	 routinely	 collected	 on	 demographic	characteristics,	 risk	 factors	 for	 VTE,	 site	 and	 extension	 of	 IDDVT,	 type	 and	duration	of	anticoagulant	treatment	and	were	retrospectively	retrieved	from	the	 center	 electronic	 database.	 Follow-up	 information	was	 retrieved	 for	 all	scheduled	 follow-up	 visits	 until	 6	 months	 from	 the	 index	 event	 and	integrated	 by	 	 a	 telephone	 contact	with	 all	 patients,	 up	 to	 at	 least	 2	 years	from	the	diagnosis	of	IDDVT.		The	 primary	 study	 outcome	was	 the	 composite	 of	 objectively	 documented	recurrent	 VTE,	 including	 IDDVT,	 proximal	 DVT,	 PE	 or	 deep	 venous	thrombosis	 in	 other	 	 sites	 .	 All	 events	 were	 locally	 adjudicated	 after	 the	evaluation	of	specific	clinical	documentation.	Proximal	DVT	was	adjudicated	if	documented	by	a	compression	or	duplex	ultrasound.	Recurrent	IDDVT	was	adjudicated	in	the	presence	of	thrombosis	of	a	previously	normal	vessel	or	in	a	 previously	 completely	 recanalized	 distal	 venous	 segment.	 PE	 was	adjudicated	 when	 documented	 by	 a	 positive	 computed	 tomography	pulmonary	angiography	or	high	probability	perfusion	lung	scan.	Secondary	outcomes	were	major	bleeding	(according	to	the	definition	of	the	International	 Society	 on	 Thrombosis	 and	 Haemostasis	 [20])	 and	 overall	mortality.	









Table	 3	 shows	 the	 results	 of	 univariate	 and	 multivariate	 analysis.	 Among	potential	predictors	of	recurrence,	only	unprovoked	IDDVT	and	the	presence	of	 active	 cancer	 remained	 significantly	 associated	 with	 recurrent	 VTE	 at	multivariate	analysis	(HR	2.11,	95%	CI	1.09-4.11,	and	HR	2.68,	95%	CI	1.13-6.36,	 respectively).	 The	 annualized	 rate	 of	 recurrent	 VTE	was	 6.8	 per	 100	patient-years	 after	 unprovoked	 IDDVT	 and	 9.7	 per	 100	 patient-years	 after	IDDVT	associated	with	active	cancer	(as	compared	with	2.2	per	100	patient-years	after	provoked	IDDVT,	p	=.004,	log-rank	test)	During	 anticoagulant	 treatment,	 6	 patients	 (1.9%)	 experienced	 major	bleeding,	 none	 was	 fatal.	 	 During	 the	 entire	 follow-up	 period,	 62	 patients	(19.3%)	died.		
















VTE),	may	 benefit	 from	 an	 extended	 treatment	 period.	 Further	 studies	 are	needed	 to	 better	 identify	 IDDVT	 patients	 who	 may	 deserve	 prolonged	anticoagulation	 and	 to	 balance	 the	 risk	 of	 recurrence	 with	 the	 risk	 of	bleeding.	
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	288	(89.7%)	13	(4.0%)	20	(6.2%)	Legend:	 SVT	 Superficial	 vein	 thrombosis;	 MPN	 myeloproliferative	 neoplasm;	 VTE	 venous	thromboembolism;	LMWH	low	molecular	weight	heparin		Table	2.	Results	Primary	outcome				Mean	follow-up				Lost	to	follow-up				Patients	diagnosed	with	recurrent	VTE							PE	(+/-	associated	DVT)							Proximal	DVT							Isolated	distal	DVT							Unusual	site	thrombosis	
	41.5	months	(SD	27.9)	8	(2.5%)	48	(15%)	15	(31.3%)	10	(20.8%)	21	(43.8%)	2	(4.2%)	Secondary	outcomes				Major	bleeding				Minor	bleeding				Cutaneous	reactions	to	LMWH	








































The	 objective	 of	 this	 review	 is	 to	 provide	 an	 evidence-based	 but	 practical	approach	 to	 anticoagulant-associated	 bleeding.	 Specifically,	 we	 aim	 to	juxtapose	 the	 management	 of	 patients	 who	 are	 receiving	 an	 ‘old	anticoagulant’	 and	bleed	with	 patients	who	develop	bleeding	while	 using	 a	‘new	anticoagulant’.	The	format	of	this	review	consists	of	illustrative	cases	of	anticoagulant-related	bleeding	 followed	by	an	evidence-based	discussion	of	our	suggested	management	approach.	
	
Management	of	anticoagulant	associated	bleeding	


































With	regard	to	the	use	of	rVIIa,	it	significantly	reduced	the	bleeding	time	that	was	 increased	 by	 dabigatran	 in	 a	 rat	 model;	 however,	 among	 coagulation	tests,	 only	 the	 PT	 returned	 to	 normal	 after	 rVIIa	 administration,	 but	 not	aPTT,	thrombin	time	and	ecarin	clotting	time.[36]	In	a	mouse	model,	rVIIa	did	not	 prevent	 intracerebral	 hematoma	 expansion	 in	 mice	 receiving	dabigatran.[33]	With	regard	to	rivaroxaban,	rVIIa	reduced	bleeding	time	that	was	 increased	by	rivaroxaban	 in	a	rat	and	a	baboon	model.[37,38]	No	clinical	data	 are	 available	 currently	 on	 the	 use	 of	 rVIIa	 for	 bleeding	 reversal	 or	 its	effects	on	coagulation	parameters	in	patients	treated	with	either	dabigatran	or	rivaroxaban.	Finally,	 hemodialysis	 can	 be	 an	 option	 only	 for	 non-highly	 protein-bound	drugs,	 such	as	dabigatran	 (and	not	 rivaroxaban	or	 apixaban).	Hemodialysis	was	 able	 to	 remove	more	 than	60%	of	dabigatran	at	2	hours	 in	 volunteers	receiving	hemodialysis	for	end-stage	renal	disease.[39]	Hemoperfusion	proved	effective	to	eliminate	dabigatran	only	in	an	in	vitro	model.[32]		Considering	 the	 paucity	 of	 available	 evidence	 regarding	 the	 reversal	 of	NOAC-associated	 bleeding,	 pragmatic	 guidance	 was	 recently	 provided	 by	members	of	North	American	thrombosis	and	hemostasis	scientific	societies.	The	use	of	FFP	was	considered	not	likely	to	be	helpful	in	this	setting,	whereas	the	use	of	PCC	was	considered	to	be	a	reasonable	approach	in	the	opinion	of	several,	but	not	all,	authors	(due	to	absence	of	clinical	data).	The	usefulness	of	rVIIa	for	new	oral	anticoagulation	reversal	was	considered	unclear.[40]			
Case	 Scenario	 3	 -	 Parenteral	 Anticoagulants	 (unfractionated	 heparin	 [UFH],	












In	 fondaparinux-treated	 patients	 with	 bleeding,	 no	 approved	 antidotes	 are	available.	 Interruption	 of	 sc	 administration	 is	 needed	 as	 the	 first	 step.	 The	use	of	FFP	and/or	PCC	 is	not	 supported	by	adequate	evidence;[50]	 activated	PCC	(FEIBA®)	significantly	 reversed	 the	action	of	 fondaparinux	 in	vitro	 in	a	single	 study.[51]	 Two	 randomized	 placebo-controlled	 trials	 on	 healthy	subjects	evaluated	the	use	of	rVIIa,	showing	its	ability	to	normalize	the	aPTT,	PT	and	thrombin-generation	time	that	were	prolonged	by	fondaparinux.[52,53]	Recently,	 a	 specific	 antidote	 has	 been	 developed	 to	 neutralize	 the	 anti-Xa	activity	of	fondaparinux	in	vivo,[54]	that	need	to	be	tested	in	the	clinical	setting	of	fondaparinux-associated	bleeding.			The	use	of	PCC,	FPP	or	rFVIIa	has	not	been	assessed,	 to	our	knowledge,	 for	UFH-	 or	 LMWH-	 or	 fondaparinux-associated	 bleeding.	 Although	 a	 clinician	may	 not	 be	 faulted	 for	 administering	 one	 or	more	 of	 these	 agents	 for	 life-threatening	 or	 severe	 intracranial	 bleeding,	 emphasis	 should	 be	 placed	 on	antidote	administration	and	other	supportive	measures.			




over	30	min.[58]	Idrabiotaparinux	is	non-inferior	to	warfarin	for	the	treatment	of	PE.[59]	Moreover,	new	antidotes	are	being	developed	in	recent	years.	Among	them,	a	recombinant	 antithrombin	 variant	 (AT-N135Q-Pro394)	 and	 a	 recombinant	factor-Xa	 variant	 (PRT064445)	 have	 shown	 to	 reverse	 the	 effect	 of	fondaparinux	 and	 LMWH	 in	 vitro	 and	 in	 animal	models.[60,61]	 Interestingly,	the	recombinant	 factor-Xa	variant	PRT064445	was	able	to	reverse	the	anti-Xa	 activity	 of	 rivaroxaban	 in	 experimental	 models,	 thus	 emerging	 as	 a	potential	antidote	to	new	oral	factor-Xa	inhibitors	for	the	clinical	setting.[60]	
	










































































































































































































































































































































































































I	 risultati	 del	progetto	di	 ricerca	hanno	portato	 ad	una	 conoscenza	più	approfondita	della	prognosi	di	due	manifestazioni	comuni	del	TEV,	come	l’EP	e	la	TVPDI.	L’analisi	dei	risultati	ha	reso	possibile	anche	la	valutazione	delle	terapie	antitrombotiche	utilizzate	per	 il	 trattamento	di	queste	patologie,	sia	in	 termini	di	efficacia	che	di	 sicurezza.	 Inoltre,	una	migliore	conoscenza	del	rischio	 e	 della	 gestione	 dei	 sanguinamenti	 in	 corso	 di	 trattamenti	anticoagulanti,	compresi	i	DOACs,	è	stata	ottenuta	grazie	ad	una	revisione	ed	analisi	 della	 letterattura.	 L’obiettivo	 iniziale	 di	 valutazione	 dell’impatto	 dei	DOACs	nel	TEV	ha	dovuto	 tuttavia	subire	una	significativa	modifica	a	causa	delle	 tempistiche	 di	 approvazione	 ed	 delle	 indicazioni	 e	 regimi	 di	rimborsabilità	 stabiliti	 da	 AIFA.	 Tuttavia,	 i	 risultati	 del	 progetto	 di	 ricerca		hanno	permesso	di	porre	delle	solide	basi	per	valutare	l’impatto	dei	DOACs	in	alcuni	ambiti	specifici	del	TEV	e,	in	particolare,	nella	gestione	dei	pazienti	con	EP	a	basso	rischio	di	complicanze	e	nella	terapia	delle	TVPDI.	Per	 quanto	 riguarda	 la	 stratificazione	 prognostica	 dell’EP	 acuta,	 i	risultati	 dallo	 studio	 LORPELHS	 hanno	 confermato	 la	 validità	 del	 PESI	nell’identificare	 i	 pazienti	 a	 basso	 rischio	 di	 mortalità	 a	 breve	 termine.	 I	risultati	 hanno	 altresì	 evidenziato	 come	 la	 durata	 del	 ricovero	 ospedaliero	per	EP	sia	ancora	piuttosto	lunga	nella	realtà	italiana,	anche	in	caso	di	basso	rischio	 di	 eventi	 avversi,	 specialmente	 se	 confrontata	 con	 le	 indicazioni	 di	linee	guida	internazionali	ed	i	risultati	di	importanti	studi	recenti.	E’	possibile	ipotizzare	che	il	solo	giudizio	clinico	standard	non	sia	in	grado	di	identificare	
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adeguatamente	questi	pazienti	a	basso	rischio	e	che,	pertanto,	l’utilizzo	di	un	semplice	 strumento	 di	 stratificazione	 prognostica,	 come	 il	 PESI,	 possa	portare	 ad	 un	 significativo	 miglioramento	 nella	 loro	 identificazione	 e	gestione.	 Questa	 considerazione	 ha	 portato	 a	 progettare	 lo	 studio	 iAPP	(Impact	 Analysis	 of	 Prognostic	 stratification	 for	 Pulmonary	 embolism),	recentemente	 approvato	 dal	 comitato	 etico	 provinciale	 di	 Varese	 (centro	coordinatore	dello	studio)	ed	in	fase	di	partenza.		I	 risultati	 dello	 studio	LORPELHS	non	hanno	evidenziato	una	 influenza	del	 tipo	 di	 terapia	 anticoagulante	 sulla	 durata	 del	 ricovero	 ospedaliero.	Tuttavia,	 questo	 risultato	 puo’	 essere	 ascritto	 alle	 diverse	 caratteristiche	basali	dei	pazienti	che	sono	stati	trattati	con	eparina+dicumarolico	rispetto	a	quelli	 trattati	 con	 sola	 eparina	 (più	 frequentemente	 oncologici).	 	 E’	ipotizzabile,	infatti,	che	la	risposta	individuale	alla	terapia	dicumarolica,	e	di	conseguenza	 il	 tempo	 per	 raggiungere	 un	 adeguato	 livello	 di	anticoagulazione,	 influenzino	 la	 durata	 del	 ricovero	 ospedaliero.	 In	quest’ottica,	 l’utilizzo	 dei	 DOACs,	 grazie	 alla	 loro	 rapidità	 d’azione	 e	prevedibilità	 farmacocinetica,	 potrebbe	 portare	 di	 per	 sé	 ad	 una	 riduzione	della	 durata	 del	 ricovero,	 indipendentemente	 dalla	 stratificazione	prognostica.	 Per	 tale	 motivo,	 nella	 fase	 di	 intervento	 del	 progetto	 (studio	iAPP)	è	stato	deciso	di	adottare	una	randomizzazione	stratificata	per	la	scelta	del	 farmaco	 anticoagulante	 (DOACs	 versus	 dicumarolico),	 al	 fine	 di	compararne	l’influenza	sulla	durata	di	ricovero.	
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Per	quanto	riguarda	il	trattamento	delle	TVPDI,	lo	studio	retrospettivo	di	coorte	 condotto	 ha	 evidenziato	 una	 incidenza	 di	 recidiva	 di	 TEV	 non	trascurabile	(15%	dei	pazienti,	4.1	per	100	anni-paziente)	e	rappresentata	da	un	evento	maggiore	 in	oltre	 la	metà	dei	 casi.	 Il	 tasso	di	 recidiva	 è	 risultato	significativamente	 più	 alto	 nei	 pazienti	 con	 un	 evento	 indice	 idiopatico	 o	associato	 ad	 una	 neoplasia	 attiva,	 ripetto	 ai	 pazienti	 che	 presentavano	 un	fattore	di	rischio	temporaneo.	Lo	 studio	 ha	 anche	 permesso	 di	 valutare	 un	 approccio	 terapeutico	 più	breve	 (EBPM	 per	 4-6	 settimane,	 utilizzato	 in	 circa	 il	 90%	 dei	 pazienti)	rispetto	 a	 quello	 attualmente	 suggerito	 dalle	 linee	 guida	 internazionali,	seppur	 con	 basso	 grado	 di	 evidenza.	 I	 risultati	 mostrano	 come	 questo	trattamento	anticoagulante	di	breve	durata	possa	essere	sufficiente	per	una	proporzione	sostanziale	di	pazienti,	come	quelli	con	TVPDI	associata	a	fattore	di	 rischio	 temporaneo.	 Al	 contrario,	 un	 trattamento	 anticogulante	 più	prolungato	 sembra	 essere	 necessaro	 in	 sottogruppi	 di	 pazienti	 a	 più	 alto	rischio	di	 recidiva,	 come	 i	pazienti	oncologici	e	quelli	 con	TVPDI	 idiopatica.	Tuttavia,	se	una	durata	di	3	mesi	sia	sufficiente	per	prevenire	 le	recidive	di	TEV	 in	 questi	 sottogruppi	 di	 pazienti,	 rimane	 da	 eseere	 stabilito	 in	 trial	clinici.			Infine,	 per	 quanto	 riguarda	 i	 sanguinamenti	 in	 corso	 di	 terapia	anticogulante,	 la	 revisione	 della	 letteratura	 ha	 portato	 a	 concludere	 che	 i	farmaci	 “convenzionali”	 e	 quelli	 di	 nuova	 generazione	 sono	 associati	 ad	 un	rischio	 clinicamente	 importante	 di	 emorragia	 maggiore,	 intorno	 al	 1-4%	
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all’anno.	E’	pertanto	fondamentale,	in	questi	casi,	mettere	in	atto	strategie	di	rapido	“reversal”	dell’azione	anticoagulante.	Le	misure	generali	di	 supporto	sono	fondamentali	in	caso	di	sanguinamenti	pericolosi	per	la	sopravvivenza,	unitamente	 a	 misure	 specifiche	 per	 antagonizzare	 l’effetto	dell’anticoagulante	coinvolto.	Al	momento,	sono	disponibili	degli	antidoti	per	l’eparina	non	 frazionata	 (solfato	di	 protamina)	 e	per	 i	 farmaci	 dicumarolici	(vitamina	 K).	 Nuovi	 antidoti,	 specificatamente	 indirizzati	 ai	 DOACs,	 sono	attualmente	in	corso	di	sperimentazione	(andexanet,	idarucizumab,	PER977)	e	potrebbero	 fornire	un	 importante	aiuto	nella	gestione	dei	 sanguinamenti,	se	la	loro	efficacia	e	sicurezza	sarà	confermata	dai	trial	clinici.			 			
